3. , , , et al. Questionable prescribing for elderly patients in Quebec. Can Med Assoc J 1994;150(11):1801–9.
4. , , . Assessing medication appropriateness in the elderly: a review of available measures. Drugs Aging 2000;16(6):437–50.
6. , , , , . Psychotropics use in the Spanish elderly: predictors and evolution between years 1993 and 2003. Pharmacoepidemiol Drug Saf 2007;16:449–57.
7. , , . Prescription médicamenteuse chez les personnes âgées. Bull Acad Natl Med 1998;182:1419–29.
8. , , , , . Evolution des traitements médicamenteux des personnes âgées vivant à domicile. Rev Méd Interne 2000;21:664–71.
9. , , , et al. Psychotropics among the home-dwelling elderly: increasing trends. Int J Geriatr Psychiatry 2002;17:874–83.
10. , , , , . Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+ study. Eur J Clin Pharmacol 2006;62:151–8.
11. , , , . Factors related to current and subsequent psychotropic drug use in an elderly cohort. J Clin Epidemiol 1997;50:357–63.
12. , , , . Correlates of psychotropic drug use in the elderly compared to adults aged 18–64: results from the Quebec Health Survey. Aging Ment Health 2001;5:216–24.
13. , . Psychosocial factors related to the use of psychotropic drugs in elderly persons. Rech Soins Infirm 2003;74:38–46.
14. , , , . Prescription psychotropic medication use among the U.S. adult population: results from the third national health and nutrition examination survey, 1988–1994. J Clin Epidemiol 2004;57:309–17.
15. , , , et al. Psychotropic medication use in Canada. Can J Psychiatry 2005;50:605–13.
16. . Psychotropic drug utilization in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiatr Scand 2004;109(Suppl. 420):55–64.
17. , , , . Kuopio 75+ study: does advanced age predict common use of psychotropics among the elderly. Int Clin Psychopharmacol 2003;18:163–7.
18. , , . Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE). Int Psychogeriatr 2004;16:461–80.
19. , , , , . Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry 2005;20:749–53.
20. , , , et al. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders. Am J Geriatr Psychiatry 2008;16:5–13.
21. , , , . Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001;49:1341–5.
22. , , , . Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 2000;157:360–7.
23. , , , , . Mental health-related drug utilization among older adults: prevalence, trends, and costs. Am J Geriatr Psychiatry 2005;13:892–900.
24. , , , et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18:425–32.
25. , . Treatment of sleep disorders in elderly patients. Curr Treat Options Neurol 2005;7:339–52.
26. , , , et al. Concomitant prescription of benzodiazepines during antidepressant therapy in the elderly. J Clin Epidemiol 2002;55:1049–53.
27. , , , et al. Benzodiazepine use among the elderly in the community. Int J Geriat Psychiatry 1999;14:280–4.
28. . Human studies of sleep and off-line memory reprocessing. In , , , eds. Sleep and Brain Plasticity. New York: Oxford University Press; 2003: pp. 41–63.
29. , , . Dreaming and the brain: toward a cognitive neuroscience of conscious states. In , , , , eds. Sleep and Dreaming. Cambridge: Cambridge University Press; 2003: pp. 1–50.
30. , , , . Are corticothalamic ‘up’ states fragments of wakefulness?Trends Neurosci 2007;30:334–42.
31. , . Slow-wave sleep and waking cognitive performance among older adults with and without insomnia complaints. Physiol Behav 1999;66:485–92.
32. , . Prefrontal cortex: links between low frequency delta EEG in sleep and neuropsychological performance in healthy, older people. Psychophysiology 2003;40:349–57.
33. , . The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nature Neurosci 2002;3:591–605.
34. . Grouping of brain rhythms in corticothalamic systems. Neuroscience 2006;137:1087–106.
35. , , , . Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 2004;27:1255–73.
36. , , . Age-related increase in awakenings: impaired consolidation of nonREM sleep at all circadian phases. Sleep 2001;24:565–77.
37. , , . Peak of the circadian melatonin rhythm occurs later within the sleep in older subjects. Am J Physiol Endocr Metab 2002;282:E297–E303.
38. , , , . Circadian patterns of sleep, sleepiness, and performance in older and younger adults. Sleep 2005;28:1365–76.
39. , , , et al. The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture. Arch Intern Med 2004;164:406–18.
40. , , , . Sleep spindles characteristics in healthy subjects of different age groups. Clin Neurophysiol 2001;112:521–7.
41. . Normal aging. In: , , , eds. Principles and Practice of Sleep Medicine,4th ed. Philadelphia: Elsevier; 2005: pp. 24–38.
42. , , . Rapid eye movement density is reduced in normal elderly. Sleep 2003;26:973–7.
43. . The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004;18:9–15.
44. , , , et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401:796–800.
45. , . The role of histamine and the tuberomammilary nucleus in the nervous system. Nat Rev Neurosci 2003;4:121–30.
46. , , , , . GABA(A) receptor heterogeneity in histaminergic neurons. Eur J Neurosci 2002;16:1472–82.
47. , , , et al. The sedative component of anaesthesia is mediated by GABA(A) receptors in endogenous sleep pathway. Nat Neurosci 2002;5:979–84.
48. , . GABAA1a receptors: involvement in sleep regulation and potential of selective agonists in the treatment of insomnia. CNS Drugs 2000;13:185–99.
49. , , . Effects of hypnotics on the sleep EEG of healthy young adults: new data and psychopharmacologic implications. J Psychiatr Res 2000;34:423–38.
50. , . Insomnia in the elderly: treatment with flurazepam hydrochloride. J Am Geriatr Soc 1979;27:541–6.
51. , , , . Daytime carryover of triazolam and flurazepam in elderly insomniacs. Sleep 1982;5:361–71.
52. . Sleep laboratory study of lormetazepam in older insomniacs. Psychopharmacology 1984;1(Suppl.):69–78.
53. , , , . Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging 1985;6:293–6.
54. , . A comparison of the effects of chlormezanone and nitrazepam on sleep. Br J Clin Sci 1982;14:57–65.
55. , . The effects of estazolam on sleep, performance, and memory: a long-term sleep laboratory study of elderly insomniacs. J Clin Pharmacol 1992;32:647–51.
56. , , , , . Hypnotic effects of low doses of quazepam in older insomniacs. J Clin Psychopharmacol 1997;17:401–6.
57. , , , , . Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep 1993;16:318–26.
58. , , , et al. Effect of zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized crossover comparative study with brotizolam. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:22–9.
59. , , , , . Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991;52:77–83.
60. , , , et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993;21:171–84.
61. , , . Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 2008;16:44–57.
62. , , , et al. Comparison of the effects of zolpidem and triazolam on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy young volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:897–910.
63. , , , . Characterization of the interaction of zopiclone with γ-aminobutyric acid type A receptor. Mol Pharmacol 2000;58:756–62.
64. , , , . Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 1990;5(Suppl 2):47–55.
65. , , , et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006;295:2851–8.
66. , , , et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006;22:1633–42.
67. , , , , . Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers. Psychopharmacology 2000;147:384–96.
68. , , , . Hypnotic residual effects of benzodiazepines with repeated administration. Sleep 1986;9:309–16.
69. , , , . Effects of seganserin, a 5-HT2 antagonist, and temazepam on human sleep stages and EEG power spectra. Eur J Pharmacol 1989;171:207–18.
70. , . Polysomnographic effects of hypnotic drugs: a review. Psychopharmacology 1996;126:1–16.
71. , , , , . Comparison of the effects of zopiclone and triazolam on the sleep of normal subjects. Encephale 1988;14:319–24.
72. , , , , . Effects of zopiclone on sleep, daytime somnolence and nocturnal and daytime performance in healthy volunteers. Neurophysiol Clin 1989;19:131–43.
73. , , , , . Relationship between the effects of a hypnotic drug, zopiclone, on polysomnography and on daytime EEGs. Neuropsychobiology 1997;35:152–5.
74. , , , et al. Comparison of the effects of zolpidem and zopiclone on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy young volunteers. Life Sci 2000;67:81–90.
75. , . Activation of GABAA receptors: views from outside the synaptic cleft. Neuron 2007;56:763–70.
76. , , , , . Tonic excitation and inhibition of neurons: ambient transmitter sources and computational consequences. Prog Biophys Mol Biol 2005;87:3–16.
77. . Extrasynaptic GABAA receptors are critical targets for sedative-hypnotic drugs. J Clin Sleep Med 2006;2:S12–8.
78. , , . Synaptic release generates a tonic GABA(A) receptor-mediated conductance that modulates burst precision in thalamic relay neurons. J Neurosci 2007;27:2560–9.
79. , , , , . Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br J Pharmacol 2002;136:965–74.
80. , , . The GABAA agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans. Psychopharmacology 1997;130:285–91.
81. , , , . The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. Sleep 2007;30:593–602.
82. , , . The GABAa agonist gaboxadol improves the quality of post-nap sleep. Psychopharmacology 2001;157:299–304.
83. , , , et al. Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia. Sleep 2007;30:281–7.
84. , , , , . Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia. Psychopharmacology 2007;195:139–46.
85. , , , . Effect of the GABAA agonist gaboxadol on nocturnal sleep and hormone secretion in healthy elderly subjects. Am J Physiol Endocrinol Metab 2001;281:E130–7.
86. , , , . Effect of repeated gaboxadol administration on night sleep and next-day performance in healthy elderly subjects. Psychopharmacology 2005;30:833–41.
87. , , , . The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 2001;22:247–53.
88. , , , et al. Dose-response effects of tiagabine on the sleep of older adults. Sleep 2005;28:673–6.
89. , , . Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 2006;29:335–41.
90. , , , , . Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 2006;7:155–61.
91. , , , . A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005–14.
92. , , , , . An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17–24.
93. , , , et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495–504.
94. . REM sleep and depression: common neurobiological control mechanisms. Am J Psychiatry 1982;139:565–570.
95. , , . Effects of antidepressant drugs on sleep EEG in patients with major depression. Mechanisms and therapeutic implications. CNS Drugs 1999;11:49–60.
96. , , , et al. Longitudinal effects of nortriptyline on EEG sleep and the likelihood of recurrence in elderly depressed patients. Neuropsychopharmacology 1996;14:243–52.
97. , , , et al. Maintenance nortriptyline effects on electroencephalographic sleep in elderly patients with recurrent major depression: double-blind, placebo- and plasma-level-controlled evaluation. Biol Psychiatry 1997;42:560–7.
98. , , , et al. Persistent effects of antidepressants: EEG sleep studies in depressed patients during maintenance treatment. Biol Psychiatry 1994;35:781–93.
99. , , , . Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983;16:139–44.
100. , , , et al. Effects of trazodone on the sleep of depressed subjects – a polygraphic study. Psychopharmacology 1988;95:S37–S43.
101. , . Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990;51(Suppl.):13–17.
102. , , . The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994;17:544–50.
103. , , , et al. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. Pharmacopsychiatry 2001;34:60–5.
104. , , , . The effect of trimipramine on sleep in patients with major depressive disorder. Pharmacopsychiatry 1986;19:198–9.
105. , , , , . Effects on sleep: a double-blind study comparing trimipramine to imipramine in depressed insomniac patients. Sleep 1989;12:537–49.
106. , , , et al. Fluoxetine in major depression: efficacy, safety and effects on sleep EEG variables. Int Clin Psychopharmacol 1990;5:253–60
107. , , , et al. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991;14:439–47.
108. , , , et al. Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 1999;20:447–59.
109. . REM sleep. In , , , eds. Principles and Practice of Sleep Medicine, 4th ed. Philadelphia: Elsevier Saunders; 2005: pp. 120–35.
110. , , , . The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–14.
111. , , . Alzheimer’s disease and other dementia. In , , , eds. Principles and Practice of Sleep Medicine, 4th ed. Philadelphia: Elsevier Saunders; 2005: pp. 853–62.
112. , , , et al. The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol 2000;35:243–9.
113. , , , et al. The effect of donepezil on sleep in elderly, healthy persons: a double-blind placebo-controlled study. Pharmacopsychiatry 2006;39:205–8.
114. , , , , . The relationship between REM sleep and memory consolidation in old age and effects of cholinergic medication. Biol Psychiatry 2007;61:750–7.
115. , , , . The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Res 1977;122:562–7.
116. , , , et al. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology 1993;8:87–92.
117. , , , , . Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatry Res 1994;51:253–67.
118. , , , et al. Effects of donepezil (Aricept) on the rapid eye movement sleep of normal subjects. Psychiatry Clin Neurosci 2002;56:307–8.
119. , , , et al. Differential effects of the muscarinic M1 receptor agonist RS-86 and the acetylcholine-esterase inhibitor donepezil on REM sleep regulation in healthy volunteers. Neuropsychopharmacology 2006;31:1294–300.
120. , , , . Effects of donepezil on Alzheimer’s disease: the relationship between cognitive function and rapid eye movement sleep. Psychiatry Clin Neurosci 2004;58:660–5.
121. , , , et al. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep 2006;29:199–205.
122. , , . Age-related effects of scopolamine on REM sleep regulation in normal control subjects: relationship to sleep abnormalities in depression. Neuropsychopharmacology 1999;21:723–30.
123. , , , et al. The effects of an orally administered cholinergic agonist on REM sleep in major depression. Biol Psychiatry 2002;51:457–62.
124. , , , . Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons. Exp Gerontol 2001;36:353–61.
125. , . Sleep function and synaptic homeostasis. Sleep Med Rev 2006;10:49–62.